Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
34142415
PubMed Central
PMC8361946
DOI
10.1002/ejhf.2275
Knihovny.cz E-zdroje
- Klíčová slova
- Advanced heart failure, Aspirin, Assist devices, Bleeding, Hemocompatibility, LVAD, Mechanical Circulatory Support, Outcomes,
- MeSH
- Aspirin MeSH
- kvalita života MeSH
- lidé MeSH
- podpůrné srdeční systémy * MeSH
- prospektivní studie MeSH
- randomizované kontrolované studie jako téma MeSH
- srdeční selhání * terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- Aspirin MeSH
AIMS: Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced. METHODS: To evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD. CONCLUSION: This paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.
Cardiology Rigshospitalet Copenhagen Denmark
Clinical Affairs Heart Failure Abbott Chicago IL USA
Department of Cardiac Surgery University of Michigan Ann Arbor MI USA
Department of Cardiovascular Surgery IKEM Prague Czech Republic
Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA
Division of Cardiology Duke University Durham NC USA
Division of Hematology Brigham and Women's Hospital Boston MA USA
Einstein Center for Heart and Vascular Care Montefiore Medical Center Bronx NY USA
Zobrazit více v PubMed
Sidhu K, Lam PH, Mehra MR. Evolving trends in mechanical circulatory support: clinical development of a fully magnetically levitated durable ventricular assist device. Trends Cardiovasc Med 2020;30:223–229. PubMed
Pinney SP, Anyanwu AC, Lala A, Teuteberg JJ, Uriel N, Mehra MR. Left ventricular assist devices for lifelong support. J Am Coll Cardiol 2017;69:2845–2861. PubMed
Mehra MR. The burden of haemocompatibility with left ventricular assist systems: a complex weave. Eur Heart J 2019;40:673–677. PubMed
Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C; MOMENTUM 3 Investigators . A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 2017;376:440–450. PubMed
Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya M, Salerno C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA, Estep JD, Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER, O'Connell JB, Heatley G, Sood P, Naka Y; MOMENTUM 3 Investigators . Two‐year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 2018;378:1386–1395. PubMed
Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Itoh A, Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh F, Aaronson K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldstein DJ; MOMENTUM 3 Investigators . A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019;380:1618–1627. PubMed
Colombo PC, Mehra MR, Goldstein DJ, Estep JD, Salerno C, Jorde UP, Cowger JA, Cleveland JC Jr, Uriel N, Sayer G, Skipper ER, Downey FX, Ono M, Hooker R Jr, Anyanwu AC, Givertz MM, Mahr C, Topuria I, Somo SI, Crandall DL, Horstmanshof DA. Comprehensive analysis of stroke in the long‐term cohort of the MOMENTUM 3 study. Circulation 2019;139:155–168. PubMed
Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald GA, Tatooles AJ, Silvestry SC, John R, Caldeira C, Jeevanandam V, Boyle AJ, Sundareswaran KS, Sood P, Mehra MR. Hemocompatibility‐related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation 2017;135:2003–2012. PubMed
Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold‐Herz M, Morshuis M, Shaw SM, Saeed D, Lavee J, Heatley G, Gazzola C, Garbade J. Two‐year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE registry. Eur Heart J 2020;41:3801–3809. PubMed
Netuka I, Ivák P, Tučanová Z, Gregor S, Szárszoi O, Sood P, Crandall D, Rimsans J, Connors JM, Mehra MR. Evaluation of low‐intensity anti‐coagulation with a fully magnetically levitated centrifugal‐flow circulatory pump – the MAGENTUM 1 study. J Heart Lung Transplant 2018;37:579–586. PubMed
Saeed O, Colombo PC, Mehra MR, Uriel N, Goldstein DJ, Cleveland J, Connors JM, Najjar SS, Mokadam NA, Bansal A, Crandall DL, Sood P, Jorde UP. Effect of aspirin dose on hemocompatibility‐related outcomes with a magnetically levitated left ventricular assist device: an analysis from the MOMENTUM 3 study. J Heart Lung Transplant 2020;39:518–525. PubMed PMC
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots – a concise summary. Vascul Pharmacol 2019;113:1–8. PubMed
Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol 2019;16:675–686. PubMed
Morris T, Stables M, Hobbs A, de Souza P, Colville‐Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. Effects of low‐dose aspirin on acute inflammatory responses in humans. J Immunol 2009;183:2089–2096. PubMed
Apostoli A, Bianchi V, Bono N, Dimasi A, Ammann KR, Moiia YR, Montisci A, Sheriff J, Bluestein D, Fiore GB, Pappalardo F, Candiani G, Redaelli A, Slepian MJ, Consolo F. Prothrombotic activity of cytokine‐activated endothelial cells and shear‐activated platelets in the setting of ventricular assist device support. J Heart Lung Transplant 2019;38:658–667. PubMed PMC
Consolo F, Sferrazza G, Motolone G, Contri R, Valerio L, Lembo R, Pozzi L, Della Valle P, De Bonis M, Zangrillo A, Fiore GB, Redaelli A, Slepian MJ, Pappalardo F. Platelet activation is a preoperative risk factor for the development of thromboembolic complications in patients with continuous‐flow left ventricular assist device. Eur J Heart Fail 2018;20:792–800. PubMed
Shah P, Tantry US, Bliden KP, Gurbel PA. Bleeding and thrombosis associated with ventricular assist device therapy. J Heart Lung Transplant 2017;36:1164–1173. PubMed
Katz JN, Adamson RM, John R, Tatooles A, Sundareswaran K, Kallel F, Farrar DJ, Jorde UP; TRACE study . Safety of reduced anti‐thrombotic strategies in HeartMate II patients: a one‐year analysis of the US‐TRACE study. J Heart Lung Transplant 2015;34:1542–1548. PubMed
Netuka I, Litzler PY, Berchtold‐Herz M, Flecher E, Zimpfer D, Damme L, Sundareswaran KS, Farrar DJ, Schmitto JD; EU TRACE Investigators . Outcomes in HeartMate II patients with no antiplatelet therapy: 2‐year results from the European TRACE study. Ann Thorac Surg 2017;103:1262–1268. PubMed
Jorde UP, Katz JN, Colombo PC, Stulak J, Saeed O, Egnaczyk G, Haeusslein E, McCann P, Crandall D, Franke A, Adamson R; PREVENT II Study Investigators . PREVENTion of non‐surgical bleeding by management of HeartMate II patients without anti‐platelet therapy (PREVENT II) trial. J Heart Lung Transplant 2020;39:838–840. PubMed
Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker MA, John R, Hathaway DR, Najarian KB, Aaronson KD; HeartWare Bridge to Transplant ADVANCE Trial Investigators . HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013;32:675–683. PubMed
Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, Tatooles AJ, Moazami N, Kormos RL, Hathaway DR, Najarian KB, Bhat G, Aaronson KD, Boyce SW; HVAD Bridge to Transplant ADVANCE Trial Investigators . An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014;33:23–34. PubMed
Lim HS, Ranasinghe A, Chue C, Mascaro J. Two‐year outcome of warfarin monotherapy in HeartMate 3 left ventricular assist device: a single‐center experience. J Heart Lung Transplant 2020;39:1149–1151. PubMed
Consolo F, Raimondi Lucchetti M, Tramontin C, Lapenna E, Pappalardo F. Do we need aspirin in HeartMate 3 patients? Eur J Heart Fail 2019;21:815–817. PubMed
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd‐Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:e177–e232. PubMed PMC
Whitlock EP, Burda BU, Williams SB, Guirguis‐Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:826–835. PubMed
Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low‐dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta‐analysis. JAMA Neurol 2019;76:906–914. PubMed PMC
Birschmann I, Dittrich M, Eller T, Wiegmann B, Reininger AJ, Budde U, Strüber M. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 2014;33:80–87. PubMed
Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor‐dependent platelet aggregation in patients with a continuous‐flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009;53:2162–2167. PubMed
Netuka I, Kvasnička T, Kvasnička J, Hrachovinová I, Ivák P, Mareček F, Bílková J, Malíková I, Jančová M, Malý J, Sood P, Sundareswaran KS, Connors JM, Mehra MR. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous‐flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant 2016;35:860–867. PubMed
Bansal A, Uriel N, Colombo PC, Narisetty K, Long JW, Bhimaraj A, Cleveland JC Jr, Goldstein DJ, Stulak JM, Najjar SS, Lanfear DE, Adler ED, Dembitsky WP, Somo SI, Crandall DL, Chen D, Connors JM, Mehra MR. Effects of a fully magnetically levitated centrifugal‐flow or axial‐flow left ventricular assist device on von Willebrand factor: a prospective multicenter clinical trial. J Heart Lung Transplant 2019;38:806–816. PubMed
Kormos RL, Antonides CFJ, Goldstein DJ, Cowger JA, Starling RC, Kirklin JK, Rame JE, Rosenthal D, Mooney ML, Caliskan K, Messe SR, Teuteberg JJ, Mohacsi P, Slaughter MS, Potapov EV, Rao V, Schima H, Stehlik J, Joseph S, Koenig SC, Pagani FD. Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the Mechanical Circulatory Support Academic Research Consortium. J Heart Lung Transplant 2020;39:735–750. PubMed
Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 2001;14:57–58, 61–62. PubMed
Kidson‐Gerber G, Weaver J, Gemmell R, Prasan AM, Chong BH. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ 2010;19:234–242. PubMed
Chivukula VK, Beckman JA, Prisco AR, Dardas T, Lin S, Smith JW, Mokadam NA, Aliseda A, Mahr C. Left ventricular assist device inflow cannula angle and thrombosis risk. Circ Heart Fail 2018;11:e004325. PubMed
Bhama JK, Bansal A. Left ventricular assist device inflow cannula position may contribute to the development of HeartMate II left ventricular assist device pump thrombosis. Ochsner J 2018;18:131–135. PubMed PMC
Mirza KK, Xie R, Cowger J, Kirklin JK, Meyns B, Gustafsson F, Shaw SM, Goldstein DJ. Comparative analysis of regional outcomes and adverse events after continuous‐flow left ventricular assist device implantation: an IMACS analysis. J Heart Lung Transplant 2020;39:904–914. PubMed
Ootaki Y, Kamohara K, Akiyama M, Zahr F, Kopcak MW Jr, Dessoffy R, Fukamachi K. Phasic coronary blood flow pattern during a continuous flow left ventricular assist support. Eur J Cardiothorac Surg 2005;28:711–716. PubMed
ClinicalTrials.gov
NCT04069156